Pramlintide Improved Measures of Glycemic Control and Body Weight in Patients With Type I Diabetes Mellitus Undergoing Continuous Subcutaneous Insulin Infusion Therapy

References

• . Young AA. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diab. 1997;4:282–290
   Google Scholar
• . Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011;12(9):1439–1451
   PubMed Web of Science ®Google Scholar
• . Weissberg-Benchell J, Antisdel-Lomaglio J, Seshardi R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;26(4):1079–1087
   PubMed Web of Science ®Google Scholar
• . Pickup JC. Insulin-pump therapy for type 1 diabetes. N Engl J Med. 2012;366(17):1616–1624
   PubMed Web of Science ®Google Scholar
• . Nicolucci A, Maione A, Franciosi M, ; EQualityl Study Group— Evaluation of QUALITY of Life and Costs in Diabetes Type 1. Quality of life and treatment satisfaction in adults with type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet Med. 2008;25(2):213–220
   PubMed Web of Science ®Google Scholar
• . Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012;367(14):1332–1340
   PubMed Web of Science ®Google Scholar
• . Bergenstal RM, Tamborlane WV, Ahmann A, ; STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–320
   PubMed Web of Science ®Google Scholar
• . Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin EndocrinolMefaft. 2012;97(12):4383–4389
   PubMed Web of Science ®Google Scholar
• . Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability: does it matter? Endocr Rev. 2010;31(2):171–182
   PubMed Web of Science ®Google Scholar
• . Weinger K, Beverly E. Barriers to achieving glycemic targets: who omits insulin and why? Diabetes Care. 2010;33(2):451–452
   Google Scholar
• . Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):240–245
   PubMed Web of Science ®Google Scholar
• . Edelman S, Garg S, Frias J, . A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29(10):2189–2195
   PubMed Web of Science ®Google Scholar
• . Karl D, Philis-Tsimikas A, Darsow T, . Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther. 2007;9(2):191–199
   PubMed Web of Science ®Google Scholar
• . Rubin RR, Peyrot M. Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use. Diabetes Educ. 2009;35(1): 136–146
   PubMedGoogle Scholar
• . Rubin RR, Peyrot M. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. Curr Med Res Opin. 2007;23(8):1919–1929
   PubMed Web of Science ®Google Scholar
• . Marrero DG, Crean J, Zhang B, . Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care. 2007;30(2):210–216
   PubMed Web of Science ®Google Scholar
• . Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med. 1991;90(4):450–459
   PubMed Web of Science ®Google Scholar
• . Picconi F, Di Flaviani A Malandrucco I, Giordani I, Frontoni S. Impact of glycemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives. Nutr Metab Cardiovasc Dis. 2012;22(9):691–696
   PubMedGoogle Scholar
• . Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006;295(14):1707–1708
   PubMed Web of Science ®Google Scholar
• . Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19(3):178–181
   PubMed Web of Science ®Google Scholar
• . Ceriello A, Piconi L, Quagliaro L, . Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care. 2005;28(3):632–637
   PubMedGoogle Scholar
• . Penckofer S, Quinn L, Byrn M, Ferrans C, Miller M, Strange P. Does glycemic variability impactmood and quality of Mel Diabetes Technol Ther. 2012;14(4):303–310
   PubMedGoogle Scholar
• . McCall AL, Cox DJ, Crean J, Gloster M, Kovatchev BP. A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. Diabetes Technol Ther. 2006;8(6):644–653
   PubMedGoogle Scholar
• . Weinzimer SA Sherr JL, Cengiz, E, . Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care. 2012;35(10):1994–1999
   PubMed Web of Science ®Google Scholar
• . Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. Diabetes Care. 2001;24(10):1711–1721
   PubMedGoogle Scholar
• . Nathan DM, Zinman B, Cleary PA ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med. 2009;169(14):1307–1316
   PubMedGoogle Scholar
• . Centers for Disease Control and Prevention. Overweight and obesity. Adult obesity facts, http://www.cdc.gov/obesity/data/trends.html. Updated August 13, 2012. Accessed November 17, 2012
   Google Scholar
• . Purneil JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998;280(2):140–146
   PubMedGoogle Scholar
• . Peyrot M, Rubin RR, Polonsky WH. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. Diabetes Technol Ther. 2008;10(6):461–466
   PubMedGoogle Scholar
• . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986
   PubMed Web of Science ®Google Scholar